{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T05:44:36Z","timestamp":1785044676843,"version":"3.55.0"},"reference-count":36,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"the Chinese Preventive Medicine Association \u201cvaccine and immunization young talent lift project\u201d","award":["CPMAQT_YM0228"],"award-info":[{"award-number":["CPMAQT_YM0228"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1080\/21645515.2021.1898306","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T19:00:04Z","timestamp":1617044404000},"page":"2568-2574","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China"],"prefix":"10.1080","volume":"17","author":[{"given":"Guodong","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenyang","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7412-5928","authenticated-orcid":false,"given":"Jun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"Global Polio Eradication Initiative. Polio eradication and endgame strategic plan 2013\u20132018. Geneva (Switzerland): World Health Organization; 2013 [accessed 2020 Oct 23]. http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/PEESP_EN_A4.pdf."},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1140041"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw567"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6535a3"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw574"},{"key":"e_1_3_4_7_1","unstructured":"China Ministry of Health. The EPI immunization schedule for children and it\u2019s instructions (2016 Edition). Beijing: China Ministry of Health; 2016 [accessed 2021 Jan 15]. http:\/\/www.nhc.gov.cn\/jkj\/s3581\/201701\/a91fa2f3f9264cc186e1dee4b1f24084.shtml."},{"issue":"12","key":"e_1_3_4_8_1","first-page":"145","article-title":"Polio Vaccines: WHO position paper-March, 2016","volume":"91","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Polio Vaccines: WHO position paper-March, 2016. Wkly Epidemiol Rec. 2016;91(12):145\u201368. [accessed 2020 Oct 23]. https:\/\/www.who.int\/wer\/2016\/wer9112.pdf?ua=1.","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00059-6"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.04.002"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6433a5"},{"key":"e_1_3_4_12_1","unstructured":"World Health Organization. Summary report on the meeting of national coordinators for poliovirus containment on the WHO global action plan to minimize poliovirus facility associated risk (GAPIII). Tunis (Tunisia); 2015 [accessed 2020 Oct 23]. https:\/\/applications.emro.who.int\/docs\/IC_Meet_Rep_2015_EN_16434.pdf."},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu128"},{"key":"e_1_3_4_14_1","unstructured":"Global Polio Eradication Initiative. Call for expressions of interest (EoI)\u2014 developing Sabin-inactivated polio vaccine (sIPV). Global Polio Eradication Initiative; 2012 [accessed 2020 Oct 23]. https:\/\/www.who.int\/immunization\/sage\/6_Polio_call_for_EOOI.pdf?ua=1."},{"key":"e_1_3_4_15_1","first-page":"213","article-title":"Guidelines for the safe production and quality control of poliomyelitis vaccines","volume":"1016","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Guidelines for the safe production and quality control of poliomyelitis vaccines. WHO Tech Rep Ser. 2019;1016:213. [accessed 2020 Oct 23]. https:\/\/www.who.int\/biologicals\/vaccines\/Annex_4_WHO_TRS_1016_web4.pdf.","journal-title":"WHO Tech Rep Ser"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.11.015"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00237-8"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30738-8"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1745593"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy736"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.023"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.073"},{"key":"e_1_3_4_23_1","first-page":"379","article-title":"Comparison of immunization safety of 4 kinds of polio vaccines in Jilin province","volume":"23","author":"Fu S","year":"2017","unstructured":"Fu S, Lin L, Cao F, Tian X, Chen T, Chen C, Huang B, Li D, Lv S, Zhou J. Comparison of immunization safety of 4 kinds of polio vaccines in Jilin province. Chin J Vaccines Immunization. 2017;23(4):379\u201382.","journal-title":"Chin J Vaccines Immunization"},{"key":"e_1_3_4_24_1","first-page":"383","article-title":"Safety of domestic Sabin strain inactivated poliovirus vaccine","volume":"23","author":"Shi X","year":"2017","unstructured":"Shi X, Zhou L, Zhou L, Liu L. Safety of domestic Sabin strain inactivated poliovirus vaccine. Chin J Vaccines Immunization. 2017;23(4):383\u201386.","journal-title":"Chin J Vaccines Immunization"},{"key":"e_1_3_4_25_1","first-page":"736","article-title":"Suspected adverse events following immunization of poliomyelitis vaccines in Hubei province: analysis on surveillance data of 2015 \u2013 2017","volume":"34","author":"Wang S","year":"2018","unstructured":"Wang S, Zhang C, Wang L, Zhao M. Suspected adverse events following immunization of poliomyelitis vaccines in Hubei province: analysis on surveillance data of 2015 \u2013 2017. Chin J Public Health. 2018;34(5):736\u201340.","journal-title":"Chin J Public Health"},{"key":"e_1_3_4_26_1","unstructured":"China Ministry of Health Food and Drug Administration of China. National guideline for the surveillance of adverse events following immunization. Beijing: China Ministry of Health Food and Drug Administration of China; 2010 [accessed 2021 Jan 15]. http:\/\/www.nhc.gov.cn\/jkj\/zcwj2\/new_zcwj_19.shtml."},{"key":"e_1_3_4_27_1","volume-title":"Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization [S]","author":"World Health Organization Regional Office for the Western Pacific","year":"2016","unstructured":"World Health Organization Regional Office for the Western Pacific. Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization [S]. 3rd ed. Manila (Philippines): World Health Organization; 2016 [accessed 2020 Oct 23]. https:\/\/www.who.int\/publications\/i\/item\/9789290617457.","edition":"3"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.09.017"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.063"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2015.11.010"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.26719\/2018.24.2.119"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2017.6.2.146"},{"issue":"2","key":"e_1_3_4_33_1","first-page":"139","article-title":"Surveillance of adverse events following immunization for inactivated poliovirus vaccine in China, in 2011\u20132013","volume":"21","author":"Li K","year":"2015","unstructured":"Li K, Ye J, Xu D, Wu W, Zhen J, Cao L, Cao L, Yuan P, Liu D, Wang H, et al. Surveillance of adverse events following immunization for inactivated poliovirus vaccine in China, in 2011\u20132013. Chin J Vaccines Immunization. 2015;21(2):139\u201346.","journal-title":"Chin J Vaccines Immunization"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2185"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.17226\/10649"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.035"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(02)00449-8"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2021.1898306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T14:59:27Z","timestamp":1709305167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2021.1898306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1080\/21645515.2021.1898306"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2021.1898306","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}